Research programme: melanocortin peptides - Mallinckrodt

Drug Profile

Research programme: melanocortin peptides - Mallinckrodt

Latest Information Update: 27 Aug 2014

Price : $50

At a glance

  • Originator Questcor Pharmaceuticals
  • Developer Mallinckrodt plc
  • Class Peptides
  • Mechanism of Action Melanocortin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation

Most Recent Events

  • 14 Aug 2014 Questcor Pharmaceuticals has been acquired by Mallinckrodt plc
  • 14 May 2014 Preclinical trials in Inflammation in USA (unspecified route)
  • 14 May 2014 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top